Slides
Page 1
© 2025 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners. 1 November 6, 2025 Invivyd Q3 Earnings Call & Business Update
Page 2
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “seek,” “could,” “intend,” “target,” “aim,” “project,” “designed to,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward- looking statements contain these identifying words. Forward-looking statements include statements concerning, among other things, expectations regarding Invivyd’s efforts to develop potential best-in-class antibody therapies across multiple viral threats; expectations about the COVID landscape; beliefs about limitations of COVID vaccines and the expected advantages of monoclonal antibodies (mAbs); expectations regarding durability and stability of the company’s antibodies; plans related to the company’s research and development activities, and the timing and potential results thereof; the potential of VYD2311 as a mAb candidate; expectations regarding the company’s clinical trial designs and enrollment, regulatory pathway, product profile, target patient population, indication and potential administration paradigm for VYD2311; PEMGARDA® (pemivibart) as a mAb for pre-exposure prophylaxis (PrEP) of COVID-19 in certain immunocompromised patients; estimates regarding the size of target patient populations and the potential market opportunity for the company’s product candidates, as well as its market position; the company’s commercialization plans, strategies, goals and expectations; the potential of the company’s pipeline and discovery efforts, including for COVID, Long COVID, respiratory syncytial virus (RSV) and measles; the company’s business strategies and objectives, and ability to execute on them; the company’s future prospects; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company’s forward-looking statements and you should not place undue reliance on the company’s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: uncertainties about the company’s expectations, projections and estimates regarding future costs and expenses, future revenue, capital requirements, and the availability of and the need for additional financing; whether the company’s cash and cash equivalents are sufficient to support its operating plan for as long as anticipated; uncertainties regarding market acceptance, payor coverage and reimbursement, or future revenue generated by PEMGARDA; the timing, progress and results of the company’s discovery, preclinical and clinical development activities, including the initiation of the DECLARATION clinical trial, and finalization and initiation of other aspects of the REVOLUTION clinical program, such as the LIBERTY clinical trial, subject to final alignment with the U.S. Food & Drug Administration (FDA); clinical trial site activation or enrollment rates; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of the company’s product candidates based on neutralizing activity in nonclinical studies; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; how long the emergency use authorization (EUA) granted by the FDA for PEMGARDA for COVID-19 PrEP in certain immunocompromised patients will remain in effect and whether such EUA is revised or revoked by the FDA; changes in the regulatory environment; the outcome of the company’s engagement with regulators; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways; the company’s ability to generate the data needed to support a potential Biologics License Application (BLA) submission for VYD2311; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of any product candidate following regulatory authorization or approval; the success of the company’s in-house sales force, and company’s ability to maintain and expand sales, marketing and distribution capabilities to successfully commercialize any authorized or approved product candidates; changes in expected or existing competition; the company’s reliance on third parties; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; variability of results in models and methods used to predict activity against SARS-CoV-2 variants; whether the epitopes that pemivibart and VYD2311 target remain structurally intact; whether the company’s product candidates are able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; the complexities of manufacturing mAb therapies, and availability of quantities of commercial launch product in the future, if authorized or approved; macroeconomic and political uncertainties; the company’s ability to realize the anticipated benefits of its loan facility; the company’s ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, each filed with the Securities and Exchange Commission (SEC), and in the company’s other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law. This presentation contains hyperlinks to information that is not deemed to be incorporated by reference in this presentation. All trademarks used in this presentation are the property of their respective owners. 2
Page 3
agenda 01 Invivyd Approach 02 Clinical & Regulatory 03 Future Commercial Landscape 04 Finance 05 Q&A 3
Page 4
The need is urgent. The market potential is significant. We’re taking action. COVID RSVLONG COVID MEASLES We’re developing potential best- in-class antibody therapies across multiple viral threats, providing protection and defining what’s next in keeping people well. With a broad pipeline and sharp execution, we’re moving quickly to turn breakthrough science into lasting impact and value. 4
Page 5
agenda 01 Invivyd Approach 02 Clinical & Regulatory 03 Future Commercial Landscape 04 Finance 05 Q&A 5
Page 6
Current Disconnected state of COVID mRNA vaccine prevention 6 References: Prescribing Information – COMIRNATY Aug 2025; Prescribing Information - SPIKEVAX Aug 2025 The Clinical Data Phase 3 RCTs: ~2 months of efficacy follow-up General Utilization Approximately annual The FDA Labels “Once – OR – More than 2 months since last boost dose”
Page 7
Screening (up to Day -14) Monitor for CLI symptoms: Day 1 to Day 90 If qualifying CLI symptoms: Confirm in-person with SARS-CoV-2 RT-PCR within 2 days If confirmed COVID: 28-day follow-up *Day 8 and Day 68 PK for ≈ 200 participants at select sites VYD2311 Placebo Placebo R 1:1:1 N1770 VYD2311-SD (single dose) VYD2311-MD (multidose) Placebo VYD2311 VYD2311 VYD2311 Placebo Placebo Placebo 60-Day Treatment Period 30-Day Follow-up Period Day 1 Day 90 End of StudyDay 30 Day 60 Screening (up to Day -14) This study will characterize the safety and tolerability, immunogenicity of COVID vaccines, pharmacokinetics of VYD2311, and neutralizing antibody titers of concomitant administrations of VYD2311 and COVID vaccines, subject to final FDA alignment. R 1:1:1 N~210 VYD2311-SD (single dose) mRNA Vaccine (single dose) Combination VYD2311 and mRNA Vaccine 30-Day Follow-up Period Day 1 End of Study 7
Page 8
Why study VYD2311 in multi-doses? Repeat dose safety and titer data Anticipate that, if approved, most people would choose to get VYD2311 once a year, with a safety profile that enables extra protection for those who want it.* 8 *Depending on Prescribing Information, if approved
Page 9
mRNA COVID vaccines side effects Invivyd COVID IM antibodies expected side effects High likelihood and High discomfort Low likelihood and Low discomfort 9
Page 10
agenda 01 Invivyd Approach 02 Clinical & Regulatory 03 Future Commercial Landscape 04 Finance 05 Q&A 10
Page 11
Foundation built to expand to a broad market Quick pivot from infused specialty medication to potential vaccine replacement Established Strong Commercial Foundation Building from Specialty Infusion Team – Scaling to serve broad market for VYD2311 Developed Focus Messaging to build from – VYD2311 requires a greater presence Access Strategy Shift to serve much larger opportunity In-line commercial team and infrastructure to support long-term growth Accounts w/ PEMGARDA Infusion Experience811 $13.1 M PEMGARDA field force sized to meet the market at centers of excellence Expanding digital presence to reach more HCP specialties Available Sites for infusion Reordering Accounts 76% All metrics are Launch to Date (LTD) - 9/30 Conferences/Exhibits Attended125+ GPO Contracted Sites15,000+ 1200+ Expand PEMGARDA market access position for VYD2311 Expanding commercial team to increase reach into broader HCP audiences Establish scalable foundation for mass consumer market PEMGARDA Net Revenue Q3 ‘25 >96% of medical claims in 2025 successfully processed Continued sales growth QoQ in 2025 11
Page 12
Broad recognition from Societies and Guidelines for Antibodies in COVID SOCIETY / GUIDELINE PEMGARDA OR MAB TARGET AUDIENCE HIV.gov PEMGARDA Immunodeficiency IDSA Pemivibart Infectious disease NCCN – B-Cell Lymphomas Pemivibart Oncology NCCN – Infection Prevention Pemivibart Oncology Immune Deficiency Foundation (IDF) PEMGARDA Immunodeficiency Leukemia and Lymphoma Society (LLS) Pemivibart Oncology MS Society PEMGARDA Rheumatology National Kidney Foundation PEMGARDA Solid organ transplant American Cancer Society PEMGARDA Oncology American College of Rheumatology mAbs Rheumatology American Lung Association Pemivibart Oncology National Council on Aging (NCOA) PEMGARDA Elderly BreastCancer.org PEMGARDA Oncology CLL Society PEMGARDA Oncology American Academy of Allergy, Asthma, and Immunology (AAAAI) PEMGARDA Immunology Vasculitis Foundation PEMGARDA Rheumatology Invivyd poised to deliver on scalable form factor for broad access 12
Page 13
COVID’s systemic complications continue to unfold 13 All trademarks and logos displayed are the property of their respective owners. Their use here is for identification purposes only and does not constitute endorsement or affiliation.
Page 14
Current market offers tailwinds for VYD2311 1 2 3 4 5 mRNA safety concerns from regulators and patients Unique non-vaccine MOA to prevent COVID provides a competitive and compelling differentiator Significant unmet need for vaccine alternatives Total addressable market is significant Growing identification of long-term effects of COVID infections 14
Page 15
COVID information-sharing tactics are scalable 15
Page 16
Commercial Congress activity 36 Congresses Planned 3 with expanded booth presence (20x20) • ASH, IDWeek, ACR Broad Focus: • Cardiology • Infectious Disease • Neurology • Nephrology • Pulmonology • Rheumatology • Transplant 16
Page 17
147M Flu Vaccine doses in 24-25 flu season 293,000,000U.S. Pop 12+ 34.2M COVID vaccinated last respiratory season ~100 - 112M Received a flu shot, but not COVID last respiratory season ~146 - 158M Did not receive COVID or flu shot in last respiratory season 17
Page 18
GOAL: provide Americans with a choice for COVID protection Reactogenic Myocarditis risk Short duration of protection (weeks) Modest efficacy Was mandated >34m doses administered in U.S. 2024-2025 season COVID-19 Vaccine Not a vaccine Immunologically silent Natural, supplemental protection Long duration of protection (months) High efficacy (anticipated) Commercial launch quantities at-the-ready Monoclonal Antibody: VYD2311 COVID mAb: potential for equitable, instant, high, safe, natural, vaccine-free protection Medical/social/political environment potentially primed for disruption of COVID vaccine Planned head-to-head safety demonstration to clearly distinguish COVID mAb from COVID vaccine VYD2311 = potential blockbuster, if approved time to go BIG 18
Page 19
$3.8B FY24 U.S. Revenue 18 and over vaccine efficacy (VE) reduction in hospitalization estimate from CDC 2023–2024 vaccine dose, ≥7 days 36% 7–59 days earlier 51% (45–56) 60–119 days earlier 42% (35–48) 120–179 days earlier 15% (3–26) COVID Vaccines: Big Revenue, Small Protection 19
Page 20
agenda 01 Invivyd Approach 02 Clinical & Regulatory 03 Future Commercial Landscape 04 Finance 05 Q&A 20
Page 21
Q1 Q2 Q3 Q4 2024 $0 $2.3M $9.3M $13.8M 2025 $11.3M $11.8M $13.1M Financial highlights Q3 2025 PEMGARDA® (pemivibart) net product revenue of $13.1 million • 41% growth over Q3 2024 • 11% growth over Q2 2025 October 2025 ending cash of over $100M • Ended Q3 2025 with $85.0 million in cash and cash equivalents after closing of $57.5 million public offering in August 2025, with additional $29.8 million gross proceeds from usage of at-the-market (ATM) offering facility in October 2025 PEMGARDA® Net Product Revenue 21
Page 22
agenda 01 Invivyd Approach 02 Clinical & Regulatory 03 Future Commercial Landscape 04 Finance 05 Q&A 22
Page 23
23